To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Mediclinic announcement in respect of Mpilo arrangements

Release Date: 16/09/2016 11:00
Code(s): MEI     PDF:  
Wrap Text
Mediclinic announcement in respect of Mpilo arrangements

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
(“Mediclinic” or the “Company”)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

16 September 2016

MEDICLINIC ANNOUNCEMENT IN RESPECT OF MPILO ARRANGEMENTS

During 2005 Mediclinic International (RF) Proprietary Limited (previously Mediclinic International
Limited (“Mediclinic SA”) implemented a black ownership initiative with MP1 Investment Holdings
Proprietary Limited (previously Circle Capital Ventures Proprietary Limited) (“MP1”) and Phodiso
Holdings Limited (“Phodiso”) (collectively, the “Strategic Black Partners”).

Following completion in February 2016 of Mediclinic SA's combination with the Company (the
“Combination”), the Company today announces that it has entered into arrangements with the
Strategic Black Partners to formalise the basis on which the Strategic Black Partners hold their shares
in the Company. These are in the same form in all material aspects as the arrangements in existence
prior to the Combination. However, the Company now receives the direct benefit of the lock-in
arrangements described below.

The arrangements that originally applied to the holdings of the Strategic Black Partners in relation to
their shares in Mediclinic SA before completion of the Combination continue to apply to their holdings
of shares in the Company such that:

-   in the case of the 24,582,960 shares held by Phodiso through its subsidiary Mpilo Investment
    Holdings 2 (RF) Proprietary Limited (“Mpilo 2”), representing approximately 3.33% of the
    Company’s issued share capital, disposals of such shares are restricted until 31 December 2018;
    and

-   in the case of the 10,958,206 shares held by MP1 through its subsidiary Mpilo 1 Newco (RF)
    Proprietary Limited (“Mpilo 1”), representing approximately 1.49% of the Company’s issued
    share capital, disposals of such shares are restricted until 31 December 2019.

The arrangements also contain pre-emptive rights in favour of the Company which provide that, if any
of the shares in the Company or shares in one of the Strategic Black Partners’ Mediclinic holding
companies are to be offered for sale, the Company will be offered the opportunity to purchase such
shares or to nominate another person to purchase such shares, in each case, at a discounted price
of, approximately, in relation to the Mpilo 1 shares, 5% to the then market value and, in relation to the
Mpilo 2 shares, 10%. Any exercise of a right to purchase such shares by the Company itself would
require the approval of its shareholders.

Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd

For further information please contact:

Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600

Date: 16/09/2016 11:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story